Background. -Digoxin is highly potent and efficacious for treatment of heart failure (HF) and/or atrial fibrillation (AF) yet compliance is often poor. Aims. -To examine prevalence rates of non-compliance with digoxin; variations between clinical settings, types of non-compliance and methods of detection; and potential factors influencing non-compliance with digoxin. Methods. -This was a systematic review and meta-analysis of prospective observational studies of non-compliance with digoxin in patients with HF and/or AF, published in English. The studies were identified through these bibliographic databases: MEDLINE, EMBASE, CINAHL, IPA and Cochrane CENTRAL. Subgroup analysis examined the influence of clinical settings, types of non-compliance and methods of detection.
Introduction
Non-compliance with medication regimens is considered as one of the major problems in patients with heart failure (HF) and/or atrial fibrillation (AF); it can lead to intoxication or missed therapeutic effects [1] [2] [3] . Digoxin is the cardiac glycoside most commonly used to treat these patients and has many positive factors: reduced morbidity, reduction of mortality at low dose and low cost with a favourable cost-effectiveness ratio [4] [5] [6] . Currently, digoxin is recommended for the treatment of the following conditions: HF in sinus rhythm with reduced left ventricular ejection fraction and symptoms of HF, despite the use of diuretics, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or aldosterone receptor antagonists [7, 8] ; AF with HF or left ventricular dysfunction [9] . Although information on compliance with this drug is regarded as one of the important factors for the effective use of digoxin in these groups of patients [10] , such information is rare. Previous systematic reviews have examined non-compliance with medications in HF patients, but limited attention has been given to the issues of study design, clinical settings, types of non-compliance and methods for detecting non-compliance [3, 11, 12] . This systematic review and meta-analysis addresses these questions by discussing the prevalence rates of non-compliance with digoxin in patients with HF and/or AF and describes potential factors influencing non-compliance with digoxin.
Methods

Data source and study selection
The inclusion criteria for our review were as follows: prospective observational studies that provided sufficient data to calculate the prevalence of non-compliance with digoxin; studies conducted in patients with congestive HF (CHF) and/or AF; studies published in English.
Outcome measures
This review focused on prevalence rates of non-compliance with digoxin as the primary outcome measure and the effect size of the associations between potential factors and noncompliance with digoxin as the secondary outcome measure.
Search strategy
The following bibliographic databases were systematically searched from their inception date to June 2012: MEDLINE, Excerpta Medica Database (EMBASE), Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts (IPA) and Cochrane CENTRAL. The key words 'digoxin'; '(non) compliance'; '(non) adherence'; '(congestive) heart failure' and 'atrial fibrillation' were used in combination with MeSH terms and EMTREE. The literature retrieval was supplemented by hand searching the reference lists of all identified articles.
Data extraction and manipulation
Data were extracted on study design and prevalence rate of non-compliance with digoxin was recorded on a data extraction form. Other information included methods for detecting non-compliance, study population, study setting, the use of digoxin (i.e. digoxin dose) and the effect size of the associations between influencing factors and non-compliance with digoxin. One study provided the effect size from both univariate and multivariate analyses [13] . The direct association between a potential factor and non-compliance from univariate analysis rather than multivariate analysis was used to determine the effect size of the association between an influencing factor and non-compliance with digoxin. One study reported prevalence rates at different points of time after discharge; we used the prevalence rate detected at the time closest to those in other included studies [14] . In addition, one study reported outcome of non-compliance as a percentage of compliance but did not define the benchmark for classification as compliant [15] ; patients who recorded a compliance percentage greater or equal to 80% were categorized as compliant [16] . Cochrane's risk of bias and the component approach were adopted for assessing study quality [17, 18] .
Data analysis
Prevalence rates of non-compliance with digoxin were calculated for each study; these were derived by dividing the number of patients who were non-compliant by the total number of patients using digoxin. The effect size (r) was calculated from exact P values when r was not reported in the original studies [19, 20] . The effect size, in behavioural science research, can be considered small when r ≤ 0.10, medium when r = 0.25 and large when r ≥ 0.40 [21] .
A statistical test of heterogeneity was performed using the Cochran-Mantel-Haenszel method. The degree of between-study heterogeneity was assessed using 2 and I 2 tests to determine whether it would be appropriate to compute a meta-analytical summary estimate [22] . The summary weighted mean differences and 95% confidence intervals (CI) were calculated based on a random-effects model using the DerSimonian-Laird method [23] . Confidence intervals for I 2 were also obtained to convey uncertainty in I 2 [24] . The results across these studies were summarized using the median and interquartile range (IQR) if there was significant heterogeneity between studies. The included studies were divided into subgroups to explore possible reasons for heterogeneity: the settings in which non-compliance had occurred (outpatient, after hospital discharge, or inpatient); the types of non-compliance (overdose or underdose); the methods for detecting noncompliance (pill count, interview, measurement of serum digoxin concentration [SDC] or combination method [interview confirmed by SDC]). If one study reported more than one method for detecting non-compliance for each type of non-compliance, we used data from objective measures (i.e. SDC measurement or combination method) for the analysis. STATA statistical software was used to perform all statistical analyses (version 10.0; StataCorp, College Station, TX, USA).
Results
Study and patient characteristics
Ten studies met the inclusion criteria, comprising a total of 1841 patients with CHF and/or AF ( Fig. 1) and covering the period 1973-2010. Eight studies reported prevalence rates of non-compliance with digoxin in outpatients [13, 14, [25] [26] [27] [28] [29] [30] , three studies reported prevalence rates after hospital discharge [13, 15, 31] and one study reported prevalence rates in inpatients [13] . A summary of the study characteristics is presented in Table 1 . The studies were undertaken in North America [29] , Europe [14, 15, 27, 28, 31] , Asia [13, 25, 26] and Africa [30] . Six studies were undertaken before the era of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers [14, 15, [28] [29] [30] [31] . All studies were conducted in older adults or the elderly. Four studies were conducted in patients with comorbidities of CHF with AF, including a total of 877 patients [13, 15, 29, 31] . The mean daily digoxin maintenance dose, the number of daily digoxin tablets and the total number of tablets of all medications reported in the included studies are also shown in Table 1 .
Non-compliance with digoxin in outpatients
Eight studies examined the prevalence of non-compliance with digoxin in outpatients (n = 1262); 491 patients were associated with non-compliance [13, 14, [25] [26] [27] [28] [29] [30] . High heterogeneity was observed in the studies in outpatients ( 2 83.40 [degrees of freedom (df) 7], P < 0.001; I 2 91.60%, 95% CI 85.85-95.02). The median prevalence rate of noncompliance with digoxin in outpatients was 43.07% (IQR 29.02-48.24%). Six studies [13, 14, 25, 26, 28, 29] reported prevalence rates of overdosing and five reported prevalence rates of underdosing [14, 26, 27, 29, 30] f At 6 months after discharge from hospital. g Seven patients were excluded because of a significant deterioration in renal function. h Each participant received one, two or four tablets daily; this was determined randomly using a Latin square design. i Medication Event Monitoring System (MEMS). j The percentage of prescribed dose taken was used to evaluate digoxin compliance but the study did not determine the definition of non-compliance; the author defined non-compliance as less than 80% of the prescribed dose taken. k Patients remaining after 6 months (n = 31; one patient died, six patients withdrew consent and two patients stopped digoxin because of adverse effects). underdosing were 23.08% (IQR 9.24-49.42%) and 25.00% (IQR 20.00-29.41%), respectively. Among six studies that reported overdosing of digoxin, five studies [13, 14, 25, 26, 28] used SDC measurement for detecting non-compliance, one study [28] used pill count and another used the combination of interview confirmed by SDC [29] . High heterogeneity was found within the studies using the SDC method ( 2 151.96 [df 4], P < 0.001; I 2 97.40%, 95% CI 95.74-98.37) in the overdosing group of outpatients. The median prevalence rate of noncompliance across the SDC measurement was 22.15% (IQR 16.00-49.42%).
The effect of detection method on the prevalence rates of non-compliance in the underdosing group of outpatients was investigated: one study used pill counts [14] , three used SDC [26, 27, 29] , two using interview [27, 29] and three used interview confirmed by SDC [27, 29, 30] . Heterogeneity within the subgroup that used the SDC method ( [26, 27, 29] . The prevalence rate of non-compliance for the underdosing group of outpatients detected by the SDC was 23.30% (95% CI 16.60-30.10%), as illustrated in Fig. 2 . However, heterogeneity was identified in the interview method subgroup ( [13, 15, 25, 29] . Three studies [13, 25, 29] reported prevalence rates of overdosing and two studies [15, 29] 
Non-compliance with digoxin after hospital discharge
Three studies reported prevalence of non-compliance with digoxin after hospital discharge (n = 84); 20 patients showed non-compliance [13, 15, 27] . Based on the heterogeneity test, these studies were homogeneous ( 2 2.98 [df 2], P = 0.225; I 2 32.90%, 95% CI 0-97.75). The pooled mean prevalence rate of non-compliance was 25.10% (95% CI 12.20-37.90%).
Non-compliance with digoxin for inpatients
Only one study examined inpatient non-compliance with digoxin (n = 518); 22 patients were associated with non-compliance [13] , representing a non-compliance rate of 4.51%.
Potential factors influencing non-compliance with digoxin
Five studies reported on potential factors influencing compliance with digoxin [13, 15, 25, 27, 29] . Twenty-four factors were identified, as shown in Table 2 . A heterogeneity test was performed in eight potential factors for noncompliance with digoxin, including: duration of therapy; understanding the medication; understanding the illness; total number of drugs prescribed; diuretic use; regularity of prescribed dose; patient age; and sex. No heterogeneity was identified within the following factors: understanding the medication; understanding the illness. Age, sex, regularity of prescribed dose, number of drugs and diuretic use were all heterogeneous ( Table 2 ). The influence was considered to be strong for six factors (regularity of prescribed dose, diuretic use, coronary artery bypass graft, implantable cardioverterdefibrillator, number of consultation visits and pill box), among which diuretic use was the strongest. Understanding the medication, number of co-morbidities, prior hospitalization for CHF and marital status showed medium effect size. The effect size for the other 14 factors was deemed to be small.
Discussion
This systematic review and meta-analysis suggests that noncompliance is a significant persisting burden that limits the effective use of digoxin in patients with HF and/or AF; nearly half of the outpatients treated with digoxin and one-fourth of patients after hospital discharge were non-compliant with therapy. In particular, two-fifths of the outpatients with co-morbidities for which digoxin was required, were non-compliant. In light of the complexity in current pharmacotherapy for patients with HF and/or AF, the present review also implies that this group was non-compliant with their other medications [12] . Multidisciplinary interventions (education and counselling during hospitalization or at home with telephone follow-ups; patient education by the pharmacist; mailing educational materials; or daily phone or video contact with patients) were identified as effective for improving compliance with HF medication, as suggested in previous studies [32] [33] [34] [35] . These findings agree with recent recommendations proposed by a French Task Force under the auspices of the French Society of Cardiology [36] . Safe and effective digoxin immunoassays may be made available for outpatients to monitor their own SDC [37, 38] . This could empower some patients to take care of their own wellbeing and may reduce the clinician's workload. However, the cost-effectiveness for the test kit should be assessed before implementation. In addition, there is a need for 'implementation' research in order to utilize such an intervention successfully in the HF population [3] . The findings from this review regarding the potential factors affecting non-compliance with digoxin could be useful for detecting patients at risk. Healthcare professionals should be aware of these factors, especially modifiable ones with strong associations between non-compliance with digoxin (e.g. concomitant use of diuretics, number of office visits or pill box). However, the findings must be interpreted with caution because the number of studies that reported such factors was limited and they were derived from univariate analyses, which may not fully reflect the complexity of non-compliance in the real world. More research on this topic needs to be undertaken before the associations between these potential factors and non-adherence to digoxin are more clearly understood.
This review is the first systematic review and metaanalysis of prospective observational studies to examine non-compliance with digoxin in real-life conditions, extending the evidence of the long-history yet contemporary medicine in terms of the prevalence rate of non-compliance, the variations in the prevalence rates according to clinical settings, types of non-compliance and methods for detecting non-compliance and the potential factors affecting non-compliance with digoxin. Well-accepted bibliographic databases were used to identify the included studies and our review adheres to standard guidelines for meta-analysis of observational studies in epidemiology [39] . This review explains many of the possible reasons for variations in non-compliance prevalence rates, which stemmed from differences in clinical settings, types of non-compliance and methods for detecting non-compliance. The interview method yielded higher prevalence rates of non-compliance compared with the SDC method. This may be because an interview, especially face-to-face, may encourage patients to report their use of medication. However, this method can be susceptible to misrepresentation and tends to result in health-care providers overestimating patient adherence [40] . SDC measurement is considered an objective method but it does not always reflect patient behaviour towards medication and may be unreliable where additional pathologies are present (e.g. impaired renal excretion or electrolyte disturbance) [41] . Furthermore, SDC cut-off points vary according to the indication. For example, an SDC of 0.5-0.9 ng/mL is suggested for patients with HF [8] but suitable SDCs for patients with accompanying conditions are lacking. Although, there is no 'gold standard' for detecting non-compliance, combining different methods (e.g. the combined method of interview confirmed by SDC) to assess non-compliance may significantly increase the quality of the data in this regard [41, 42] .
Despite our efforts to explain the heterogeneity, variations remain for the studies that reported overdosing of digoxin employing the SDC method. This may be explained by differences in the SDC cut-off points for non-compliance. Although this review might have missed some studies that met the inclusion criteria by restricting the search to English publications only, hand searching of the reference lists was used as a supplementary method to maximize the number of identified publications. While Cochrane's risk of bias was adopted to assess the quality of the studies, such criteria are more suitable for assessing the methodological quality of randomized studies [43] ; this precludes such an assessment in our review.
Conclusions
In summary, non-compliance is prevalent among patients with HF and/or AF treated with digoxin. The effectiveness of digoxin in contemporary treatment of HF and/or AF would be improved if the risk of non-compliance with digoxin could be minimized to a level that causes no harm to patients and achieves the therapeutic effect.
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